Century Therapeutics develops allogeneic cell therapies to treat various types of cancers, focusing on solid tumors and hematological malignancies. Its lead product is CNTY-101, an allogeneic CAR-iNK cell therapy that targets CD19 for relapsed B-cell lymphoma. The company has also developed several other product candidates for different types of cancers.